Ardelyx (ARDX) Financials: History & Chart

Ardelyx, Inc.(ARDX)

Biotechnology · Waltham, MA

$3.24-0.15 (-4.42%)

Delayed quote: Oct 6, 2026, 1:05 PM EDT

About Ardelyx, Inc.

Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.

Waltham, MA

489 employees

www.ardelyx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael G. Raab

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	450.89M	120.88M	94.47M	125.22M	110.33M	97.66M	74.11M	116.13M	98.24M
Cost of Goods Sold	27.23M	5.76M	4.81M	11.77M	4.89M	13.03M	12.90M	18.26M	15.73M
Gross Profit	423.67M	115.12M	89.66M	113.44M	105.44M	84.63M	61.21M	97.86M	82.51M
Gross Profit Margin	94.0%	95.2%	94.9%	90.6%	95.6%	86.7%	82.6%	84.3%	84.0%
Total Operating Expenses	459.12M	127.54M	122.45M	108.35M	100.77M	99.02M	97.56M	89.74M	80.28M
Research & Development	85.39M	26.10M	20.19M	21.93M	17.16M	15.04M	14.34M	13.67M	15.31M
Selling, General & Administrative	373.73M	101.44M	102.27M	86.41M	83.61M	83.99M	83.22M	76.07M	64.97M
Operating Income (EBIT)	-35.45M	-12.43M	-32.79M	5.10M	4.67M	-14.39M	-36.35M	8.13M	2.23M
Operating Margin	-7.9%	-10.3%	-34.7%	4.1%	4.2%	-14.7%	-49.0%	7.0%	2.3%
Income Before Tax (EBT)	-55.48M	-16.61M	-37.60M	-400K	-867K	-19.08M	-40.28M	4.68M	-766K
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	27.43M	4.96M	6.92M	7.58M	7.98M	6.58M	6.26M	5.85M	5.28M
Other Income/Expense	-20.02M	-4.19M	-4.80M	-5.50M	-5.54M	-4.68M	-3.94M	-3.44M	-3.00M
Net Income	-55.70M	-16.72M	-37.60M	-407K	-969K	-19.08M	-41.14M	4.64M	-809K
Income Tax Expense	227K	110K	8K	7K	102K	1K	859K	35K	43K
Net Profit Margin	-12.4%	-13.8%	-39.8%	-0.3%	-0.9%	-19.5%	-55.5%	4.0%	-0.8%
EBITDA	-31.19M	-10.91M	-31.88M	6.02M	5.57M	-13.76M	-35.75M	8.64M	2.78M
EBITDA Margin	-6.9%	-9.0%	-33.7%	4.8%	5.1%	-14.1%	-48.2%	7.4%	2.8%
Depreciation & Amortization	4.26M	1.52M	915K	921K	905K	631K	602K	515K	544K
EPS Basic	-0.23	-0.07	-0.15	-0.00	-0.00	-0.08	-0.17	0.02	-0.00
EPS Diluted	-0.23	-0.07	-0.15	-0.00	-0.00	-0.08	-0.17	0.02	-0.00
Weighted Average Basic Shares	248.07M	248.07M	245.86M	243.61M	241.91M	239.93M	238.62M	237.37M	235.91M
Weighted Average Diluted Shares	248.07M	248.07M	245.86M	243.61M	241.91M	239.93M	238.62M	244.05M	235.91M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	407.32M	333.62M	124.46M	52.16M	10.10M	7.57M	5.28M	2.61M
Cost of Goods Sold	42.60M	50.56M	17.80M	4.12M	1.00M	145K	600K	466K
Gross Profit	364.72M	283.06M	106.66M	48.04M	9.10M	7.43M	4.68M	2.14M
Gross Profit Margin	89.5%	84.8%	85.7%	92.1%	90.1%	98.1%	88.6%	82.1%
Total Operating Expenses	405.70M	311.01M	169.94M	111.80M	163.44M	98.21M	95.94M	93.09M
Research & Development	68.47M	52.32M	35.54M	35.20M	91.14M	65.05M	71.68M	69.37M
Selling, General & Administrative	337.23M	258.69M	134.40M	76.60M	72.30M	33.15M	24.27M	23.71M
Operating Income (EBIT)	-40.98M	-27.95M	-63.28M	-63.76M	-154.35M	-90.78M	-91.26M	-90.95M
Operating Margin	-10.1%	-8.4%	-50.8%	-122.2%	-1528.6%	-1199.0%	-1728.1%	-3488.6%
Income Before Tax (EBT)	-60.63M	-38.87M	-65.52M	-67.20M	-158.16M	-94.31M	-94.64M	-91.29M
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	28.40M	20.09M	8.87M	5.07M	4.50M	5.10M	5.73M	3.53M
Other Income/Expense	-19.65M	-10.92M	-2.24M	-3.44M	-3.81M	-3.53M	-3.37M	-347K
Net Income	-61.60M	-39.14M	-66.07M	-67.21M	-158.16M	-94.31M	-94.94M	-91.30M
Income Tax Expense	969K	266K	547K	8K	4K	2K	303K	4K
Net Profit Margin	-15.1%	-11.7%	-53.1%	-128.9%	-1566.5%	-1245.7%	-1797.8%	-3502.0%
EBITDA	-37.92M	-25.89M	-61.98M	-62.62M	-151.54M	-86.81M	-86.92M	-88.27M
EBITDA Margin	-9.3%	-7.8%	-49.8%	-120.0%	-1500.8%	-1146.6%	-1646.0%	-3385.8%
Depreciation & Amortization	3.06M	2.06M	1.29M	1.14M	2.81M	3.97M	4.34M	2.68M
EPS Basic	-0.26	-0.17	-0.30	-0.42	-1.52	-1.05	-1.47	-1.62
EPS Diluted	-0.26	-0.17	-0.30	-0.42	-1.52	-1.05	-1.47	-1.62
Weighted Average Basic Shares	241.03M	235.23M	219.33M	158.69M	104.21M	89.58M	64.48M	56.22M
Weighted Average Diluted Shares	241.03M	235.23M	219.33M	158.69M	104.21M	89.58M	64.48M	56.22M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.